CEO Buys 250K BioStem Shares, Signaling Confidence Amid 40% Decline
CEO buy‑back at $2.00 signals confidence in BioStem’s regenerative‑medicine pipeline, yet investors face volatile stock, negative P/E, and regulatory risk. Click to learn how insider moves could reshape value.
3 minutes to read